Therefore, our results demonstrated the aberrant expression of miR‐145‐5p in NRAS‐mutant and wild‐type melanomas which correlated with MAPK and PI3K/AKT pathways and provided novel target for the therapy of NRAS‐mutant and wild‐type melanomas. This evidence concerns the gene AKT1 and melanoma.